INTRODUCTION
Recent media coverage has raised awareness of the issue of drugs in the crime of`date' or`acquaintance' rape (Frintner and Rubinson, 1993; Koss et al., 1998; Masters, 1997; Peipert and Domagalski, 1994) . The term`date rape drug' has been coined to refer to substances used to intoxicate or incapacitate potential victims, rendering them more vulnerable to sexual assault and less able to remember details of the events surrounding the crime. The label has been applied to certain speci®c substances because of their alleged properties. These include the benzodiazepine,¯unitrazepam (Rohypnol) (Anglin et al., 1997; Simmons and Cupp, 1998; Woods and Winger, 1997) ; gamma hydroxybutyrate (GHB) (Masters, 1997; Anonymous, 1997) ; and ketamine, a general anaesthetic (Merle, 1997) .
Flunitrazepam was introduced in 1975. Since then, it has been marketed in over 80 countries, and some 250 million courses of treatment have been prescribed. Flunitrazepam is indicated for the treatment of insomnia and as an anaesthetic premedication. Although dierences in potency between¯unitrazepam and diazepam have been reported in a misleading way by certain media, the 1 mg tablets of¯unitrazepam are clinically equipotent to diazepam, 10 mg (Heinzl and Hossli, 1978; Mattila and Larni, 1980) .
The hypnotic eect of¯unitrazepam is more powerful than its anxiolytic, muscle-relaxant and anticonvulsant actions (Hindmarch, 1977 (Hindmarch, , 1990 . Sedation occurs about 20±30 min after a therapeutic (oral) dose of 1±2 mg, peaks within 1±2 h and may persist for 6±8 h Mattila and Larni, 1980) , thought it has few residual eects once the period of sleep has passed (Hindmarch, 1990; Harrison et al., 1985) . Flunitrazepam may be particularly appropriate for sleep at unusual times (Nicholson et al., 1980) .
As with other benzodiazepines,¯unitrazepam causes anterograde amnesia Ð this is considered to be an advantage in its use as a preoperative medication (Hindmarch, 1990; Subhan and Hindmarch, 1984) . The combination of benzodiazepines, including¯unitrazepam, with alcohol can lead to profound sedation and anterograde amnesia (Hindmarch, 1990; Subhan and Hindmarch, 1983) .
Concerns over reports of¯unitrazepam in connection with`date rape' led the manufacturer of Rohypnol (¯unitrazepam) to undertake an educational campaign in the USA warning of the dangers of drug-assisted sexual assault. F. Homan-La Roche Ltd. has reformulated its 1 mg tablet to change the shape, colour, coating, marking and packaging to deter any illicit misuse of the drug, whilst maintaining safety and ecacy for legitimate patients. Following reports of the potential for this and many other drugs and substances to be used in sexual assault, Roche has added a dye to the tablet which releases a bright blue colour as it dissolves in liquid. The new tablet is strongly coloured and dissolves more slowly than the old formulation. These changes and the blue colour make it more easy to detect if it should be covertly put into someone's drink. As of December 1998, 21 countries, including Colombia, Argentina and Mexico, from which there are concerns that illegal tracking of¯unitrazepam to the USA has occurred, had approved the new formulation.
Despite the widespread media interest, there has been little proven evidence and no systematic investigation of the incidence of drug use in the crime of sexual assault (Saum and Inciardi, 1997; Calhoun et al., 1996) . A study was therefore instigated in the USA to assess the extent to which alcohol and other drugs were present in samples taken from victims of rape where substances were allegedly involved (ElSohly and Salamone, submitted).
METHOD
ElSohly Laboratories, an independent, US Government-certi®ed forensic toxicology laboratory, has set up a testing facility (Ledray, 1997) available in the USA to law enforcement agencies, hospital emergency departments and rape crisis centres involved in the investigation of sexual assaults in which misuse of a drug was alleged. The present report describes the currently available results of this ongoing programme, which is funded by Roche Laboratories. Urine samples were collected over a period of 24 months, from June 1996 to May 1998, as described by ElSohly and Salamone (submitted). This period was arbitrarily divided into an initial phase (June 1996±July 1997) and a secondary phase (August 1997±May 1998) to facilitate the identi®cation of trends in the pattern of drug use in sexual assault.
The samples were tested by OnLine immunoassay (Crouch et al., 1998; Salamone et al., 1997; ElSohly and Salamone, submitted) for the presence of amphetamines, barbiturates, benzodiazepines (50 ng/ml cut-o), benzoylecgonine, cannabinoids, methaqualone, opiates, phencyclidine and propoxyphene. Positive results were con®rmed by gas chromatography±mass spectrometry (GC±MS). The samples were also tested for gamma hydroxybutyrate by GC±MS and for alcohol by gas chromatography±¯ame ionization detection. Ketamine was not included in the analysis because intoxication with this drug is easily identi®able.
Flunitrazepam can be dicult to detect in urine samples. Because of its potency, it is administered in doses that are relatively small compared to other benzodiazepines. However, a recently developed method (ElSohly et al., 1997; ElSohly and Salamone, submitted; Valentine et al., 1996) is able to detect low concentrations of 7-aminounitrazepam, the major urinary metabolite of unitrazepam. The technique uses a highly speci®c and sensitive GC±MS analysis which has a detection limit of less than 1 ng/ml. This procedure can con®rm the presence of¯unitrazepam metabolites in urine at least 72 h after ingestion of a 1 mg dose of the drug (ElSohly et al., 1997; Salamone et al., 1997) .
Samples were submitted with anonymous caserecord forms which recorded the place and time of the assault and when the sample was taken (ElSohly and Salamone, submitted).
RESULTS
During the initial phase, 388 samples were submitted for analysis; these were followed by a further 645 in the secondary phase, making a total of 1033 samples. Additionally, 11 samples could not be Copyright # 1999 John Wiley & Sons, Ltd. Hum. Psychopharmacol. Clin. Exp. 14, 225±231 (1999 analysed as the specimens leaked in transit. Table 1 gives the cumulative totals of the test results for these samples by drug. Note that these ®gures relate to the number of positive and negative tests, rather than samples (123 samples were positive for more than one drug). Composite ®gures for stimulants (amphetamines and cocaine), CNS depressants (ethanol, barbiturates, GHB and benzodiazepines, including¯unitrazepam), and illicit drugs (GHB, cannabinoids, opiates, cocaine, and amphetamines) are provided in Table 2 . Again, these ®gures relate to the number of positive tests as some samples were positive for more than one drug. Table 3 summarizes the sample set, giving the total numbers of positive and negative samples and the total numbers of positive tests.
To identify trends in the data, a growth factor was calculated for each of the drugs by dividing the number of positive tests at the end of the second period by those at the end of the ®rst phase. When About 41 per cent of the specimens were negative (i.e. no drugs were detected). In the positive samples (at least one drug found), nearly 20 dierent substances were detected, with alcohol being the most common (37 per cent of all samples tested) followed by cannabinoids (18 . 5 per cent). During the ®rst period (i.e. from June 1996±July 1997), four samples of 138 tested (1 . 2 per cent) were positive for¯unitrazepam. Two further samples were positive for¯unitrazepam during the second phase (August 1997±May 1998). The cumulative total for¯unitrazepam was six of the 1033 samples tested (0 . 6 per cent). Of these, four samples contained other drugs, including alcohol, cocaine and/or morphine. Thus, in only 0 . 2 per cent of samples was¯unitrazepam detected alone Ð it may be the case that alcohol was missed in these cases due to delay between ingestion and sampling.
As Table 1 indicates, the index of change (0 . 56) was lowest for¯unitrazepam, GHB and codeine in comparison to the other drugs, implying a decreasing incidence of positive detections. The group of non-¯unitrazepam benzodiazepines has the second lowest index value (0 . 82). In contrast, the index values for ethanol (1 . 27), cannabinoids (1 . 46), barbiturates (1 . 25) and amphetamines (1 . 33) indicate an increasing frequency of positive samples over time. Hum. Psychopharmacol. Clin. Exp. 14, 225±231 (1999) Interestingly, as Table 2 shows, the composite ®gures and respective indices for CNS depressants (1 . 03), stimulants (1 . 15) and illicit drugs (1 . 11) tend to equalize the sub-trends of individual substances, indicating a relatively unchanging frequency of detection in these composite groups.
The proportionate representation of the dierent drugs in all of the samples is illustrated by Figure 1 . Overall, the most commonly detected drug was alcohol, which was present in 113 (29 per cent) of samples at the beginning of the monitoring period and in 382 (37 per cent) at the end. Figure 2 illustrates the cumulative totals of negative samples, and positive samples by drug, over the second phase of the study.
DISCUSSION
The overall incidence of¯unitrazepam in samples taken from rape victims where substances were suspected was very low (0 . 6 per cent) compared to other benzodiazepines (12 . 5 per cent) and alcohol (37 per cent). Only 0 . 2 per cent of samples contained¯unitrazepam alone Ð the others contained cocaine, alcohol and/or morphine. Due to the interval between ingestion and sampling, alcohol may have been missed in the¯unitraze-pam-alone samples. Furthermore, the index of change in incidence showed a trend towards a decreasing frequency of samples that were positive for¯unitrazepam.
The majority (86 . 1 per cent) of samples were taken within 48 h of the alleged drug ingestion, and 97 . 5 per cent of the urine samples were taken within the sensitivity range of 72 h for¯unitrazepam (Figure 3 ). Given the very low incidence rate of samples positive for¯unitrazepam, it is unlikely that further positive samples would have escaped detection due to late urine sampling in the remaining 26 cases.
The relatively large number of negative samples (41 per cent) cannot be easily explained. Given the data on the time intervals from alleged drug ingestion to urine sampling and the time limits for detection, it is unlikely that benzodiazepines (includinḡ unitrazepam), opioids or cannabinoids have been missed. In fact, a somewhat disproportionate overrepresentation of these drugs might be expected due to their plasma elimination half-lives. Conversely, it is likely that alcohol, amphetamines and cocaine are Hum. Psychopharmacol. Clin. Exp. 14, 225±231 (1999) under-represented for the same reason. The temporal and causal relationship between the substances detected and the alleged assaults is unknown for reasons of con®dentiality.
The results indicate a considerable degree of multiple drug use, particularly alcohol combined with various other drugs, which may not be surprising in the context of what is already published about`date' or`acquaintance rape'. The test results also indicate a rather high incidence of illicit drugs, which may be related to the ®nding that female drug abusers are at a higher risk of being assaulted (Kilpatrick et al., 1997) . Illicit drugs and alcohol are known to be signi®cant risk factors for rape (Abbey, 1991; Hammock and Richardson, 1997; Harrington and Leitenberg, 1994; Dinero, 1989, Muehlenhard and Linton, 1987; Stormo et al., 1997) .
Despite media reports, these results do not support the labelling of¯unitrazepam as a`date rape drug'. The incidence of samples positive for unitrazepam was very low, and the trend for detection, if any, decreased over time. Survey research among typical patient populations with sleep and anxiety disorders suggests that¯unitra-zepam is characteristic of benzodiazepines in that it is used appropriately and conservatively, with low liability for abuse (Woods and Winger, 1997) . Currently, over one million patients in 80 countries take¯unitrazepam for insomnia and related disorders. For these legitimate users of the drug, unitrazepam remains a valuable, safe and eective hypnotic.
